Gujarat Themis Biosyn Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 387.65 as of 12 Jun 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Gujarat Themis Biosyn Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Windlas Biotech Ltd for the Mar '26 is ₹ 242.85 crore as compare to the Dec '25 revenue of ₹ 237.67 crore. This represent the growth of 2.18% The ebitda of Gujarat Themis Biosyn Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Windlas Biotech Ltd for the Mar '26 is ₹ 29.64 crore as compare to the Dec '25 ebitda of ₹ 28.95 crore. This represent the growth of 2.38% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 15.99 crore over 8 quarters. This represents a CAGR of 8.91% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Windlas Biotech Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,224 Cr while Market cap of Windlas Biotech Ltd is 1,694 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd?

As of June 14, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹387.65. On the other hand, Windlas Biotech Ltd stock price is INR ₹821.1.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.